An Open-Label Biomarker Study of BHV-1300 in Graves' Disease

Biohaven Therapeutics Ltd.

Summary

The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.

Eligibility

Age range: 18–65 years
Sex: All
Healthy volunteers: No

Detailed criteria

Key Inclusion Criteria: 1\. Participants must have serologically confirmed Graves' Disease. Key Exclusion Criteria: 1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter) and/or history of thyroid storm within six weeks of the Baseline visit. 2. History of treatment with radioactive iodine or thyroid surgery.

Interventions

Drug
BHV-1300
BHV-1300 is delivered subcutaneously (SC)

Locations (13)

Site-103
South Gate, California
Site-100
Miami, Florida
Site-104
Columbus, Georgia
Site-106
Houston, Texas
Site-101
Houston, Texas
Site-105
Shavano Park, Texas